Last reviewed · How we verify
NCT01426191: SWSB
A Open Multi-center Clinical Study on Cefotaxime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary Tract Infection
trial testing xinzhijun in Respiratory Tract Infections in 2,032 participants. Completed in 1 December 2016.
1 April 2015
Quick facts
| Lead sponsor | Xiangbei Welman Pharmaceutical Co., Ltd |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,032 |
| Start date | 1 August 2011 |
| Primary completion | 1 April 2015 |
| Estimated completion | 1 December 2016 |
Drugs / interventions tested
- xinzhijun — full drug profile →
Conditions studied
- Respiratory Tract Infections — all drugs for Respiratory Tract Infections →
- Urinary Tract Infections — all drugs for Urinary Tract Infections →
Sponsor
Xiangbei Welman Pharmaceutical Co., Ltd — full company profile →
Who can join
18 and older, any sex, with Respiratory Tract Infections or Urinary Tract Infections. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Number of Participants With Adverse Events
Time frame: day0-day22-28
the incidence(%)of allergies, skin rashes, shock,death, etc.
Sponsor's own description
In the proposed study, the investigators plan to evaluate the efficacy and safety of Cefotaxime sodium and sulbactam sodium for injection (2:1)for the treatment of respiratory and urinary tract acute bacterial infection under the widely used in clinical conditions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01426191
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Respiratory Tract Infections
Currently open trials in the same condition.
- NCT07207291 — Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers · Phase 1 · recruiting
- NCT06715306 — Intravenous Versus Oral Treatment of the Main Acute Infections · NA · recruiting
- NCT06472219 — PREDICATE Trial For Respiratory Tract Infections · Phase 3 · recruiting
- NCT05914324 — Outpatient Pediatric Pulse Oximeters in Africa · NA · recruiting
- NCT06579170 — Burden of Recreational Water Illness Due to Exposure to Cyanobacteria and Their Toxins in Freshwater Beaches in Canada · active not recruiting
Other Xiangbei Welman Pharmaceutical Co., Ltd trials
Trials by the same sponsor.
- NCT04202068 — A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea · Phase 4 · completed
- NCT04066621 — PHase IV Clinical Trial of Ceftriaxone Sodium and Sulbactam Sodium for Injection (CRO-SBT) · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01426191 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiangbei Welman Pharmaceutical Co., Ltd
- Last refreshed: 11 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01426191.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing